Status and progress of Icotinib in treatment of EGFR-mutant non-small cell lung carcinoma

Abstract

Lung cancer has a high incidence and mortality worldwide. Among them, non-small cell lung cancer (NSCLC) accounts for the majority. In terms of treatment, targeted therapy is a more effective option for NSCLC patients with genetic mutations when compared with chemotherapy. Currently, there are a number of targeted drugs targeting different mutations in NSCLC on the market, among which, icotinib (Conmona®) is an oral small molecule epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). It’s approved as first-line treatment for locally advanced or metastatic NSCLC patients with EGFR-mutant, for monotherapy to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen (primarily platinum-based combination chemotherapy) and approved as postoperative adjuvent therapy for stage Ⅱ-ⅢA NSCLC with EGFR-mutant in China. What’s more, there are many other usages and further clinical trials are underway. Here, we review the status and progress of icotinib in the treatment of EGFR-mutant NSCLC.